1610P Humoral immune response to COVID-19 vaccination in patients with cancer: The ANRS0001S COV-POPART study

Liêm Binh Luong Nguyen; M. Chalouni; P. Loubet; N. Dohollou; O. Tredan; M. Veyri; Z. Maakaroun-Vermesse; I. Ben Ghezala; E. Fourn; D. Merrien; C. Cracowski; A. Barquin; A. Levier; L. Wittkop; O. Launay; Jean Yves Blay; J-P. Spano

doi:10.1016/j.annonc.2022.07.1703

Article2025

Humoral immune response to Covid-19 vaccination in patients with cancer – Results from the ANRS0001S COV-POPART study

Liem Binh Luong Nguyen, Lyvia Magloire, Alexis François, David Billard, Frank Priou, Jennifer Arrondeau, Claude Linassier, Inès Ben Ghezala, Marine Gross‐Goupil, J. Charles, Nadine Dohollou, Philippe Vanhems, Claire Cracowski, Anne‐Marie Leroi, Fabrice Lainé, Florence Galtier, Karine Barthélémy, Stéphane Priet, Mariam Gharib, Mathieu Chalouni, Aude Barquin, Paul Loubet, Xavier de Lamballerie, Odile Launay, Linda Wittkop, Jean Yves Blay, Jean‐Philippe Spano

Article2022

84. One-month Humoral Response Following Two Doses of Covid-19 Vaccines in Specific populations – ANRS0001S COV POPART Cohort Study

Paul Loubet, L I nda Wittkop, Mathieu Chalouni, David Laplaud, Martine Laville, Bruno Laviolle, Jean‐Daniel Lelièvre, Jean Yves Blay, Benoı̂t Barrou, Benjamin Terrier, Laure Esterle, Stéphanie Nguyen, Axel Levier, Éric Tartour, Xavier de Lamballerie, Odile Launay

Article2024

Association between humoral serological markers levels and risk of SARS-CoV-2 infection after the primary COVID-19 vaccine course among ANRS0001S COV-POPART cohort participants

Mathieu Chalouni, Paul Loubet, Edouard Lhomme, Läétitia Ninove, Benoı̂t Barrou, Jean Yves Blay, Maryvonne Hourmant, de Sèze, Martine Laville, Bruno Laviolle, Jean‐Daniel Lelièvre, Jacques Morel, Stéphanie Nguyen Quoc, Jean‐Philippe Spano, Benjamin Terrier, Anne Thiébaut, Jean‐François Viallard, François Vrtovsnik, Sophie Circosta, Aude Barquin, Mariam Gharib,

Preprint2024

Association between humoral serological markers levels and risk of SARS-CoV-2 infection after the primary COVID-19 vaccine course among ANRS0001S COV- POPART cohort participants

Mathieu Chalouni, Paul Loubet, Edouard Lhomme, Läétitia Ninove, Benoı̂t Barrou, Jean Yves Blay, Maryvonne Hourmant, de Sèze, Martine Laville, Bruno Laviolle, Jean‐Daniel Lelièvre, Jacques Morel, Stéphanie Nguyen Quoc, Jean‐Philippe Spano, Benjamin Terrier, Anne Thiébaut, Jean‐François Viallard, François Vrtovsnik, Sophie Circosta, Aude Barquin, Mariam Gharib,

Article2021

Immunological Response to COVID-19 Vaccination in Ovarian Cancer Patients Receiving PARP Inhibitors

Michalis Liontos, Evangelos Terpos, Christos Markellos, Flora Zagouri, Αlexandros Briasoulis, Ioanna Katsiana, Efthymia Skafida, Oraianthi Fiste, Elena Kunadis, Αngeliki Andrikopoulou, Maria Kaparelou, Konstantinos Koutsoukos, Maria Gavriatopoulou, Efstathios Kastritis, Ioannis P. Trougakos, Meletios A Dimopoulos

1610P Humoral immune response to COVID-19 vaccination in patients with cancer: The ANRS0001S COV-POPART study

Discussion(0)

Related publications

Humoral immune response to Covid-19 vaccination in patients with cancer – Results from the ANRS0001S COV-POPART study

84. One-month Humoral Response Following Two Doses of Covid-19 Vaccines in Specific populations – ANRS0001S COV POPART Cohort Study

Association between humoral serological markers levels and risk of SARS-CoV-2 infection after the primary COVID-19 vaccine course among ANRS0001S COV-POPART cohort participants

Association between humoral serological markers levels and risk of SARS-CoV-2 infection after the primary COVID-19 vaccine course among ANRS0001S COV- POPART cohort participants

Immunological Response to COVID-19 Vaccination in Ovarian Cancer Patients Receiving PARP Inhibitors